Target intelligence / Profile preview

RAB7A-interacting MON1-CCZ1 complex subunit 1 (RIMOC1)

Target
RIMOC1
Molecular classification
Other (does not fit standard families like \"receptor\", \"enzyme\", \"transcription factor\", \"ion channel\"; classified as a protein complex subunit and regulatory factor), Protein complex subunit
01

Overview

RAB7A-interacting MON1-CCZ1 complex subunit 1 (RIMOC1) is a cytosolic and nucleoplasmic protein that plays a key role in the removal of damaged mitochondria via mitophagy. It does so by controlling the stability and localization of RAB7A, a small GTPase involved in late endosome/lysosome trafficking. RIMOC1 is required for the recruitment of RAB7A and ATG9A vesicles to mitochondria, and it promotes the stability of RAB7A by inhibiting its proteasomal degradation during mitophagy. While diseases such as Osteochondritis dissecans and Charcot-Marie-Tooth Disease are associated with this gene, there is currently no evidence that RIMOC1 serves as a direct therapeutic target, nor are there drugs targeting it specifically[1][3][5][7]. Its main classification is as a protein complex subunit involved in mitochondrial quality control.

Other names
C5orf51LOC285636UPF0600 protein C5orf51RIMOC1RAB7A-interacting MON1-CCZ1 complex subunit 1
02

Mechanism of action

None identified (no drugs targeting RIMOC1 directly; biological role is regulatory in mitophagy rather than direct pharmacological action)

03

Biological functions

Mitophagy (autophagic removal of damaged mitochondria)Stabilization and localization of RAB7ARecruitment of vesicles to damaged mitochondria (including ATG9A vesicles)Inhibition of proteasomal degradation of RAB7A
04

Disease associations

Osteochondritis dissecansCharcot-Marie-Tooth DiseaseOther (potential relevance to diseases involving mitochondrial quality control and neurodegeneration, though direct disease mechanisms are less well established)
05

Safety considerations

None documented (no notable therapeutic safety concerns as there are no drugs targeting RIMOC1)
06

Interacting drugs

None identified (no approved or investigational drugs specifically listed as interacting with RIMOC1)
07

Biomarkers

None identified (not currently in common use as a biomarker for patient selection or monitoring efficacy)

Beyond the preview

Go deeper on RAB7A-interacting MON1-CCZ1 complex subunit 1 (RIMOC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAB7A-interacting MON1-CCZ1 complex subunit 1 (RIMOC1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call